Urinary Cell Levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and Acute Rejection of Human Renal Allografts

被引:47
|
作者
Afaneh, Cheguevara [1 ]
Muthukumar, Thangamani [2 ,3 ]
Lubetzky, Michelle [2 ]
Ding, Ruchuang [2 ]
Snopkowski, Catherine [2 ]
Sharma, Vijay K. [2 ,4 ]
Seshan, Surya [5 ]
Dadhania, Darshana [2 ,3 ,4 ]
Schwartz, Joseph E. [6 ]
Suthanthiran, Manikkam [2 ,3 ]
机构
[1] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Surg, New York, NY USA
[2] New York Presbyterian Hosp, Weill Cornell Med Ctr, Div Nephrol & Hypertens, Dept Med, New York, NY USA
[3] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Transplantat Med, New York, NY USA
[4] Rogosin Inst, New York, NY USA
[5] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Pathol, New York, NY USA
[6] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA
基金
新加坡国家研究基金会;
关键词
Acute rejection; OX40; Costimulation; Urinary biomarkers; RESPONSES IN-VIVO; COSTIMULATORY PATHWAYS; ALLOIMMUNE RESPONSES; TRANSPLANT RECIPIENTS; T-CELLS; TOLERANCE; ACCEPTANCE; SURVIVAL; BLOCKING; MEMORY;
D O I
10.1097/TP.0b013e3181ffbadd
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The positive costimulatory proteins OX40 and OX40L and negative regulatory proteins programmed death (PD)-1, PD ligand 1, and PD ligand 2 have emerged as significant regulators of acute rejection in experimental transplantation models. Methods. We obtained 21 urine specimens from 21 renal allograft recipients with graft dysfunction and biopsy-confirmed acute rejection and 25 specimens from 25 recipients with stable graft function and normal biopsy results (stable). Urinary cell levels of mRNAs were measured using real-time quantitative polymerase chain reaction assays, and the levels were correlated with allograft status and outcomes. Results. Levels of OX40 mRNA (P < 0.0001, Mann-Whitney test), OX40L mRNA (P = 0.0004), and PD-1 mRNA (P = 0.004), but not the mRNA levels of PD ligand 1 (P = 0.08) or PD ligand 2 (P = 0.20), were significantly higher in the urinary cells from the acute rejection group than the stable group. Receiver operating characteristic curve analysis demonstrated that acute rejection is predicted with a sensitivity of 95% and a specificity of 92% (area under the curve = 0.98, 95% confidence interval 0.96-1.0, P < 0.0001) using a combination of levels of mRNA for OX40, OX40L, PD-1, and levels of mRNA for the previously identified biomarker Foxp3. Within the acute rejection group, levels of mRNA for OX40 (P = 0.0002), OX40L (P = 0.0004), and Foxp3 (P = 0.04) predicted acute rejection reversal, whereas only OX40 mRNA levels (P = 0.04) predicted graft loss after acute rejection. Conclusion. A linear combination of urinary cell levels of mRNA for OX40, OX40L, PD-1, and Foxp3 was a strong predictor of acute rejection in human renal allograft biopsies. This prediction model should be validated using an independent cohort of renal allograft recipients.
引用
收藏
页码:1381 / 1387
页数:7
相关论文
共 50 条
  • [31] Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
    Javan, Mohammad Reza
    Aslani, Saeed
    Zamani, Mohammad Reza
    Rostamnejad, Javad
    Asadi, Milad
    Farhoodi, Mahdi
    Nicknam, Mohammad Hossein
    IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2016, 15 (04) : 296 - 302
  • [32] INTRAHEPATIC EXPRESSION OF PD-1, PD-L1 AND PD-L2 IN CHRONIC HEPATITIS B PATIENTS
    Chen, J.
    Lan, M. -D.
    Wu, X. -J.
    Zhao, J. -M.
    Lan, Z. -W.
    Wang, G-Q
    JOURNAL OF HEPATOLOGY, 2009, 50 : S205 - S205
  • [33] Association of PD-1, PD-L1 and PD-L2 expression with clinicopathological factors in tongue squamous cell carcinoma
    Tsuchihashi, Kei
    Nakatsugawa, Munehide
    Asanuma, Hiroko
    Miyazaki, Akihiro
    Torigoe, Toshihiko
    CANCER SCIENCE, 2018, 109 : 498 - 498
  • [34] PD-1/PD-L1 blockade in renal cell cancer
    Beckermann, Kathryn E.
    Johnson, Douglas B.
    Sosman, Jeffrey A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (01) : 77 - 84
  • [35] Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
    Suszczyk, Dorota
    Skiba, Wiktoria
    Zardzewialy, Witold
    Pawlowska, Anna
    Wlodarczyk, Karolina
    Polak, Grzegorz
    Tarkowski, Rafal
    Wertel, Iwona
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [36] OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum
    van der Sluis, Tetje C.
    Beyrend, Guillaume
    Gracht, Esme T. I. van der
    Abdelaal, Tamim
    Jochems, Simon P.
    Belderbos, Robert A.
    Wesselink, Thomas H.
    Duikeren, Suzanne van
    Haften, Floortje J. van
    Redeker, Anke
    Ouboter, Laura F.
    Nejad, Elham Beyranvand
    Camps, Marcel
    Franken, Kees L. M. C.
    Linssen, Margot M.
    Hohenstein, Peter
    Miranda, Noel F. C. C. de
    Mei, Hailiang
    Bins, Adriaan D.
    Haanen, John B. A. G.
    Aerts, Joachim G.
    Ossendorp, Ferry
    Arens, Ramon
    CELL REPORTS MEDICINE, 2023, 4 (03)
  • [37] PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma
    Stevenson, Valentina B.
    Perry, Samantha N.
    Todd, Michelle
    Huckle, William R.
    LeRoith, Tanya
    VETERINARY PATHOLOGY, 2021, 58 (04) : 692 - 698
  • [38] TARGETING PD1/PD-L1/PD-L2 SIGNALING IN ENDOMETRIOSIS
    Mamillapalli, Ramanaiah
    Golden, Adriana
    Taylor, Hugh S.
    Gawde, Nimisha
    FERTILITY AND STERILITY, 2023, 120 (04) : E307 - E307
  • [39] AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer
    Spirina, L. V.
    Avgustinovich, A. V.
    Afanas'ev, S. G.
    Kondakova, I. V.
    Volkov, M. Yu.
    Dobrodeev, A. Yu.
    Boronkina, A. I.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 170 (01) : 75 - 78
  • [40] Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
    Zak, Krzysztof M.
    Grudnik, Przemyslaw
    Magiera, Katarzyna
    Domling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    STRUCTURE, 2017, 25 (08) : 1163 - 1174